Literature DB >> 16842401

Selectivity of NSAIDs for COX-2 and cardiovascular outcome.

S R J Maxwell1, R A Payne, G D Murray, D J Webb.   

Abstract

BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) with increased selectivity for the cyclooxygenase-2 (COX-2) isoform reduce gastrotoxicity but may increase adverse cardiovascular events.
METHODS: We searched the literature for studies that reported the odds ratio (OR) for such events following exposure to NSAIDs.
RESULTS: For studies comparing NSAID use with no use, increased COX-2 selectivity was significantly related to cardiovascular risk (log OR) amongst observational studies (R = -0.34, P < 0.001) and randomized controlled trials (RCTs) (R = -0.56, P < 0.001). For studies comparing NSAIDs, difference in selectivity was related to risk for observational studies (R = -0.28, P = 0.005) but not for RCTs (R = -0.23, P = 0.15).
CONCLUSIONS: Although increased COX-2 selectivity may reduce gastrotoxicity, this may be at the cost of increasing cardiovascular risk.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16842401      PMCID: PMC1885096          DOI: 10.1111/j.1365-2125.2006.02620.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  6 in total

Review 1.  Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.

Authors:  M M Wolfe; D R Lichtenstein; G Singh
Journal:  N Engl J Med       Date:  1999-06-17       Impact factor: 91.245

Review 2.  Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic.

Authors:  Timothy D Warner; Jane A Mitchell
Journal:  FASEB J       Date:  2004-05       Impact factor: 5.191

3.  COX-2 selective inhibitors--important lessons learned.

Authors:  Simon R J Maxwell; David J Webb
Journal:  Lancet       Date:  2005 Feb 5-11       Impact factor: 79.321

4.  Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.

Authors:  Julia Hippisley-Cox; Carol Coupland
Journal:  BMJ       Date:  2005-06-11

5.  Role of prostacyclin in the cardiovascular response to thromboxane A2.

Authors:  Yan Cheng; Sandra C Austin; Bianca Rocca; Beverly H Koller; Thomas M Coffman; Tilo Grosser; John A Lawson; Garret A FitzGerald
Journal:  Science       Date:  2002-04-19       Impact factor: 47.728

6.  Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2.

Authors:  B F McAdam; F Catella-Lawson; I A Mardini; S Kapoor; J A Lawson; G A FitzGerald
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

  6 in total
  1 in total

Review 1.  Clinical Pharmacology and Cardiovascular Safety of Naproxen.

Authors:  Dominick J Angiolillo; Steven M Weisman
Journal:  Am J Cardiovasc Drugs       Date:  2017-04       Impact factor: 3.571

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.